GlassScriptPhysician profile
Mateo Betanzos
NPI 1457767998
$10,206.10
in general payments reported to CMS, 2019-2025
19 companies · $858 in 2025
The $858 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,302 · 2022: $1,967 · 2023: $4,620 · 2024: $1,459 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,588 · Consulting Fee: $2,475 · Travel and Lodging: $873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,588.00 |
| Consulting Fee | $2,475.00 |
| Travel and Lodging | $873.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $6,082.17 | 2021-2025 | Apretude, Dovato, Cabenuva |
| Gilead Sciences, INC. | $1,313.07 | 2021-2025 | |
| Janssen Biotech, INC. | $627.89 | 2021-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $541.80 | 2021-2025 | Pifeltro, Delstrigo, Gardasil 9 |
| Abbvie INC. | $535.18 | 2022-2024 | |
| Theratechnologies INC. | $291.75 | 2022-2024 | Egrifta, Trogarzo |
| Janssen Products, LP | $136.35 | 2021 | |
| Napo Pharmaceuticals INC | $113.78 | 2021-2024 | Mytesi |
| Emd Serono, INC. | $90.60 | 2021-2024 | |
| Indivior INC. | $87.47 | 2022-2024 | Perseris |
| Janssen Pharmaceuticals, INC | $72.94 | 2021-2022 | |
| Exact Sciences Corporation | $65.90 | 2024 | Cologuard Collection Kit |
| Neurocrine Biosciences, INC. | $57.95 | 2022-2023 | Ingrezza |
| Pfizer INC. | $46.43 | 2023 | |
| Glaxosmithkline, LLC. | $34.54 | 2024-2025 | Rotarix, Bexsero, Pediarix |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $31.97 | 2021 | |
| Novo Nordisk INC | $31.65 | 2025 | Wegovy |
| Boston Scientific Corporation | $27.95 | 2025 | General - Thrombectomy |
| Biogen, INC. | $16.71 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mateo Betanzos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.